<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10970684</article-id><article-id pub-id-type="pmc">2374669</article-id><article-id pub-id-type="pii">6691401</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1401</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A randomized phase II study of SRL172 (<italic>Mycobacterium vaccae</italic>) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>O&#x02019;Brien</surname><given-names>M E R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Saini</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>I E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Webb</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gregory</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mendes</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ryan</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Priest</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bromelow</surname><given-names>K V</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Palmer</surname><given-names>R D</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Tuckwell</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Kennard</surname><given-names>D A</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Souberbielle</surname><given-names>B E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Royal Marsden Hospital NHS Trust, Sutton, Surrey SM2 5PT</aff><aff id="aff2"><label>2</label>Kent Cancer Centre, Maidstone, ME16 9QQ</aff><aff id="aff3"><label>3</label>Dept of Molecular Medicine, King&#x02019;s College, London, SE5 9NU</aff><aff id="aff4"><label>4</label>Department of Bacteriology, University College London Medical School, W1P 6DB</aff><aff id="aff5"><label>5</label>SR Pharma, 26th Floor, Centre Point, 103 New Oxford Street, London, WC1A 1DD, UK</aff><aff id="aff6"><label>6</label></aff><pub-date pub-type="epub"><day>04</day><month>09</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2000</year></pub-date><volume>83</volume><issue>7</issue><fpage>853</fpage><lpage>857</lpage><history><date date-type="received"><day>02</day><month>12</month><year>1999</year></date><date date-type="rev-recd"><day>29</day><month>05</month><year>2000</year></date><date date-type="accepted"><day>22</day><month>06</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Mycobacterial preparations have been used with limited success against cancer apart from superficial bladder cancer. Recently, a therapeutic vaccine derived from <italic>Mycobacterium vaccae</italic> has been given to patients with prostate cancer and melanoma indicating a possible beneficial effect on disease activity in such patients. We have recently initiated a series of randomized studies to test the feasibility and toxicity of combining a preparation of heat-killed <italic>Mycobacterium vaccae</italic> (designated SRL172) with a multidrug chemotherapy regimen to treat patients with inoperable non-small cell lung cancer (NSCLC) and mesothelioma. 28 evaluable patients with previously untreated symptomatic NSCLC and mesothelioma were randomized to receive either 3 weekly intravenous combination chemotherapy alone, or chemotherapy given with monthly intra-dermal injections of SRL172. Safety and tolerability were scored by common toxicity criteria and efficacy was evaluated by survival of patients and by tumour response assessed by CT scanning. The toxicity of chemotherapy was similar in the two groups. SRL172 caused mild inflammation at the injection site. In the group of patients randomized to receive chemotherapy combined with SRL172, there was a trend towards improved response rate (54&#x00025; vs. 33&#x00025;) with more patients in the combined arm receiving radical surgery and radiotherapy, improved median survival (9.7 months vs. 7.5 months) and improved 1 year survival (42&#x00025; vs. 18&#x00025;). SRL172 appeared to improve sleep (<italic>P</italic> = 0.08) and improved appetite (<italic>P</italic> = 0.01). There was no detectable change in serum cytokine levels for gamma-interferon and TNF-&#x003b1; before and after treatment. In patients with NSCLC and mesothelioma, there may be a beneficial interaction when chemotherapy is administered in combination with SRL172. Confirmation of this effect and further investigation is underway in a randomized phase III trial and in laboratory models. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>lung cancer</kwd><kwd>mesothelioma</kwd><kwd>SRL172</kwd><kwd>mycobacterium vaccae</kwd><kwd>chemotherapy</kwd></kwd-group></article-meta></front></article>


